Form 4: BioXcel Therapeutics Director Michal Votruba Reports Stock Option Grant and Assignment

Director Michal Votruba reports the grant and immediate assignment of stock options to RSJ Investments SICAV a.s.

Summary

• Michal Votruba, a director of BioXcel Therapeutics, Inc., filed a Form 4 on June 11, 2024, reporting a transaction that occurred on June 10, 2024.
• Votruba was granted stock options to purchase 17,000 shares of BioXcel Therapeutics common stock at an exercise price of $1.44.
• The options vest on the earlier of the first anniversary of the grant date or the day before the next annual meeting, contingent on continued service as a non-employee director.
• Votruba immediately and automatically assigned these stock options to RSJ Investments SICAV a.s. (RSJ) due to RSJ's stock ownership policies.
• Votruba does not beneficially own any of the reported securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock option grants and assignments, with no inherent positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to stock option grants to a company director and their subsequent assignment, which is not uncommon in situations where directors are affiliated with investment firms that have specific stock ownership policies.

Related Party Transactions

• The assignment of stock options from Michal Votruba to RSJ Investments SICAV a.s. is a related party transaction.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it involves the grant and assignment of stock options to a director and an affiliated investment firm.

Key Dates

Keywords

Form 4, BioXcel Therapeutics, BTAI, Stock Options, Director, Votruba, RSJ Investments, Beneficial Ownership, Assignment